Mary Norine Walsh, MD, immediate past president of the American College of Cardiology, discusses the symptoms of peripartum cardiomyopathy, and who is at the highest risk for developing it.
Mary Norine Walsh, MD, immediate past president of the American College of Cardiology, discusses the symptoms of peripartum cardiomyopathy, and who is at the highest risk for developing it.
Transcript
What are the symptoms of peripartum cardiomyopathy, and who is at high risk for this condition?
Peripartum cardiomyopathy remains a somewhat rare disease, although it occurs in women generally within the last month of pregnancy up to about 5 months after delivery.
The signs and symptoms are those generally of heart failure of any kind: Shortness of breath, fatigue, [and] inability to do activities of daily living which is a condition we call effort intolerance. Any type of symptom like that that a woman experiences later on in her pregnancy or after delivery has to be discussed with her physician rapidly and she needs to seek care.
We know a little bit more about this disease than we did in the past due to some growing registries that have helped support information on the disease. We do know that it is more common in older women, in women who have hypertension during pregnancy, and in women who have more than a singleton birth. But there is a lot we don't know because there is a lot of variability in the incidence of peripartum cardiomyopathy.
The most important information for women to have is what the signs and symptoms are so she can promptly present for care if needed.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Intermountain Healthcare and Story Health Partner to Optimize Rural Heart Failure Care
February 7th 2023On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.
Listen
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More